Conclusion
There is no question that there is a critical global need for an HIV vaccine that can protect all people from the varying HIV viruses circulating around the world. This effort has been woefully underfunded and underprioritized. HIV vaccine development is now beginning to get more of the attention it deserves and resources are slowly following. It is clear that the world should be investing far more in the search for a vaccine and prioritizing the creation of vaccines that will be appropriate for use where the epidemic is spreading most rapidly. Furthermore, it is clear that a system must be put in place to assure that all those who need a vaccine will have access to one, regardless of their economic or social status. The latter relies heavily on international efforts to aggressively move R&D forward and to begin to prepare for success.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Binswanger HP. Scaling up HIV/AIDS programs to national coverage. Science, 2000;288:2173–2176.
Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet, 2000;356:1423–1430.
World Health Organization. Ad Hoc Committee on Health Research Relating to Future Intervention Options, Investing in Health Research for Development. TDR/Gen/96.1. Geneva: World Health Organization, 1996.
Peltola H. What would happen if we stopped vaccination? Lancet, 2000;356(Suppl):s22.
Gangarosa EJ, Galazka AM, Wolfe CR, et al. Impact of anti-vaccine movements on pertussis control: The untold story. Lancet, 1998;351:356–361.
The World Bank. World Development Report 1993; Investing in Health. New York: Oxford University Press, 1993:72–73.
Global Alliance for Vaccines and Immunization website. Available at: www.vaccinealliance.org. Accessed February 3, 2002.
Mercer Management Consulting. A commercial perspective of vaccine supply. New York: Report to UNICEF by Mercer Management Consulting, 1994.
Batson A. Win-win interactions between the public and private sectors. Nat Med, Vaccine Supplement, 1998;4:487–491.
Gregersen, Jens-Peter. Vaccine Development: The Long Road from Initial Idea to Product Licensure. In: Levine M, ed. New Generation Vaccines, 2nd Ed. New York: Marcel Dekker, 1997:1165–1177.
The Economist. The Pharmaceutical Industry: The alchemists. The Economist, Insert, February 21,1998.
Glaser V. Number of biotechnology companies pursuing HIV vaccines begins to dwindle. Genetic Engineering News, 1997; 17:14,44.
The International AIDS Vaccine Initiative. AIDS Vaccines for the World: Preparing now to assure access. July 2000. The International AIDS Vaccine Initiative website. Available at www.iavi.org. Accessed February 3, 2002.
Danzon PM. The Economics of Parallel Trade. Pharmacoeconomics, 1998; 13:293–304.
International AIDS Vaccine Initiative website. Available at: www.iavi.org. Accessed February 3, 2002.
Galloway, MR. The IAVI Report, 1999:4(5):1,14.
Esparza J, Bhamarapravati N. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? Lancet, 2000;355:WA15–WA20.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic Publishers
About this chapter
Cite this chapter
Berkley, S. (2002). The Need for a Vaccine. In: Essex, M., Mboup, S., Kanki, P.J., Marlink, R.G., Tlou, S.D., Holme, M. (eds) AIDS in Africa. Springer, Boston, MA. https://doi.org/10.1007/0-306-47817-X_38
Download citation
DOI: https://doi.org/10.1007/0-306-47817-X_38
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-46699-1
Online ISBN: 978-0-306-47817-8
eBook Packages: Springer Book Archive